Abstract
Mycobacterial infections (particularly, tuberculosis caused by Mycobacterium tuberculosis) represent a significant threat to public health, especially south of the Sahara. The problem has been compounded by poor patient compliance due to long periods of treatment, thus resulting in the development of multi-drug resistant (MDR) and extremely drugresistant (XDR) forms the of bacterium. It has, therefore, become imperative to seek new drugs from unexplored sources against these infections. Natural products, from ancient times, have often been used as drugs for the treatment of various ailments. They have also served as templates for the design and synthesis of new drugs. In sub-Saharan Africa particularly, ethnobotanical and ethnomedical knowledge of plants has been exploited to manage several different ailments, including tuberculosis. Thus research efforts have often been concentrated on plants as a source of treatment of diseases as well as drug leads. In this mini review, we report the biological activities of compounds derived from African medicinal plants with the potential for the treatment of anti-mycobacterial infections. Seventy nine (79) antimycobacterial compounds have been identified in sub-Sahara Africa covering the period from 1995 to 2013.
Keywords: Drug discovery, medicinal plants, mycobacterial infections, natural products, tuberculosis.
Anti-Infective Agents
Title:Potential Natural Antimycobacterial Metabolites from Some Sub-Saharan Medicinal Plants
Volume: 12 Issue: 2
Author(s): Joseph N. Yong and Fidele Ntie-Kang
Affiliation:
Keywords: Drug discovery, medicinal plants, mycobacterial infections, natural products, tuberculosis.
Abstract: Mycobacterial infections (particularly, tuberculosis caused by Mycobacterium tuberculosis) represent a significant threat to public health, especially south of the Sahara. The problem has been compounded by poor patient compliance due to long periods of treatment, thus resulting in the development of multi-drug resistant (MDR) and extremely drugresistant (XDR) forms the of bacterium. It has, therefore, become imperative to seek new drugs from unexplored sources against these infections. Natural products, from ancient times, have often been used as drugs for the treatment of various ailments. They have also served as templates for the design and synthesis of new drugs. In sub-Saharan Africa particularly, ethnobotanical and ethnomedical knowledge of plants has been exploited to manage several different ailments, including tuberculosis. Thus research efforts have often been concentrated on plants as a source of treatment of diseases as well as drug leads. In this mini review, we report the biological activities of compounds derived from African medicinal plants with the potential for the treatment of anti-mycobacterial infections. Seventy nine (79) antimycobacterial compounds have been identified in sub-Sahara Africa covering the period from 1995 to 2013.
Export Options
About this article
Cite this article as:
Yong N. Joseph and Ntie-Kang Fidele, Potential Natural Antimycobacterial Metabolites from Some Sub-Saharan Medicinal Plants, Anti-Infective Agents 2014; 12 (2) . https://dx.doi.org/10.2174/2211352512666140417002335
DOI https://dx.doi.org/10.2174/2211352512666140417002335 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Metallopharmaceuticals in Therapy - A New Horizon for Scientific Research
Current Medicinal Chemistry The Economics of Polypharmacology: Fixed Dose Combinations and Drug Cocktails
Current Medicinal Chemistry Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates
Current Drug Discovery Technologies Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology Fracture Risk Associated with Use of Antibiotics
Current Drug Safety Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Current Pharmaceutical Design Context-Dependent Regulation of Nrf2/ARE Axis on Vascular Cell Function during Hyperglycemic Condition
Current Diabetes Reviews Natural Compounds for Overcoming Multidrug Resistance in Mycobacteria
Recent Patents on Biotechnology Cyclopentenyl Fatty Acids: History, Biological Activity and Synthesis
Current Topics in Medicinal Chemistry Neglected Diseases - New Compounds and Treatments
Current Medicinal Chemistry Controlling Pathogenic Gram-Negative Bacteria by Interfering with Their Biofilm Formation
Drug Design Reviews - Online (Discontinued) Synthesis and Antibacterial Activity of Some Novel 1-(4-Oxo-3-(3- methoxyphenyl)-3H-quinazolin-2-yl)-4-(substituted) thiosemicarbazides
Anti-Infective Agents Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Lipid-based Nanocarriers Loaded with Taxanes for the Management of Breast Cancer: Promises and Challenges
Current Drug Targets Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging The Malarial Drug Target Plasmodium falciparum 1-Deoxy-D-Xylulose-5- Phosphate Reductoisomerase (PfDXR): Development of a 3-D Model for Identification of Novel, Structural and Functional Features and for Inhibitor Screening (Supplementary Information)
Protein & Peptide Letters